NASDAQ, DVAX - Dynavax Technologies
Dynavax Technologies Corporation is a biopharmaceutical company that discovers,
develops and intends to commercialize innovative Toll-like Receptor 9, or TLR9,
agonist-based products to treat and prevent infectious diseases, allergies,
cancer and chronic inflammatory diseases using versatile, proprietary approaches
that alter immune system responses in highly specific ways. Our TLR9 agonists
are based on immunostimulatory sequences, or ISS, which are short DNA sequences
that enhance the ability of the immune system to fight disease and control
chronic inflammation.
Our product candidates include: HEPLISAV(tm), a hepatitis B vaccine in Phase 3
partnered with Merck & Co. Inc.; TOLAMBA(tm), a ragweed allergy therapy in Phase
2; a therapy for metastatic colorectal cancer in Phase 1; and a therapy for
hepatitis B in Phase 1. Our preclinical asthma and chronic obstructive pulmonary
disease (COPD) program is partnered with AstraZeneca AB. ...
Read SEC Filing on NASDAQ.com »